Bristol Myers Squibb (BMY) Amortizatization of Intangibles (2009 - 2012)
Bristol Myers Squibb's (BMY) quarterly Amortizatization of Intangibles came in at $102.0 million in Q2 2012, up 7.37% year-over-year from $95.0 million in Q3 2011, and up 0.99% quarter-over-quarter from $101.0 million in Q1 2012.
Analysis
Bristol Myers Squibb (BMY) Amortizatization of Intangibles (2009 - 2012) Analysis & Trends
Bristol Myers Squibb (BMY) has reported Amortizatization of Intangibles for 4 consecutive years, with $102.0 million the latest figure, recorded in Q2 2012.
- On a quarterly basis, Amortizatization of Intangibles rose 7.37% year-over-year to $102.0 million in Q2 2012; TTM through Jun 2012 was $388.0 million, a 26.38% increase from a year earlier, with the FY2011 full-year figure at $353.0 million, up 30.26% from the prior year.
- Amortizatization of Intangibles was $102.0 million for Q2 2012 at Bristol Myers Squibb, up from $101.0 million in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $102.0 million in Q2 2012 and troughed at $59.0 million in Q3 2009.
- A 4-year average of $80.3 million and a median of $75.5 million in 2009 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles slipped 6.41% in 2010 and soared 41.79% in 2011, its largest moves.
- Over 4 years, Amortizatization of Intangibles stood at $78.0 million in 2009, then fell by 6.41% to $73.0 million in 2010, then climbed by 26.03% to $92.0 million in 2011, then increased by 10.87% to $102.0 million in 2012.
- The last three Amortizatization of Intangibles figures came in at $102.0 million (Q2 2012), $101.0 million (Q1 2012), and $92.0 million (Q4 2011), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 984.00 Mn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | - |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | 4.33 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2012 | 102.00 Mn |
| Mar 31, 2012 | 101.00 Mn |
| Dec 31, 2011 | 92.00 Mn |
| Sep 30, 2011 | 93.00 Mn |
| Jun 30, 2011 | 95.00 Mn |
| Mar 31, 2011 | 73.00 Mn |
| Dec 31, 2010 | 73.00 Mn |
| Sep 30, 2010 | 66.00 Mn |
| Jun 30, 2010 | 67.00 Mn |
| Mar 31, 2010 | 65.00 Mn |
| Dec 31, 2009 | 78.00 Mn |
| Sep 30, 2009 | 59.00 Mn |